NEORAL
LOE ApproachingNDAORALCAPSULE
Approved
May 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
NEORAL by Novartis is clinical pharmacology cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. Approved for organ rejection in kidney, liver, heart allogeneic transplants and 2 more indications. First approved in 1997.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEORAL (cyclosporine) is a potent immunosuppressive small molecule that selectively inhibits T-lymphocyte activation in the G0 and G1 phases of the cell cycle. It is indicated for prevention of organ rejection in kidney, liver, and heart allogeneic transplants, as well as for rheumatoid arthritis and severe psoriasis in nonimmunocompromised patients. The drug works by reversibly suppressing cell-mediated immune responses and inhibiting lymphokine production, particularly interleukin-2.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling smaller team focus on legacy brand defense and transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. Cyclosporine has been demonstrated to suppress some humoral immunity and to a…
Worked on NEORAL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.